ClinicalTrials.gg
Active, not recruitingNCT06846541ONWARD3Updated Apr 13, 2026

Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis

A Phase 3 interventional study of Open-Label Envudeucitinib and Blinded Envudeucitinib in Plaque Psoriasis, Psoriasis (PsO) and Psoriasis, sponsored by Alumis Inc. Active, not recruiting at 268 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by Alumis Inc · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,680
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 764 studies in Psoriasis with a site in United States — 55 open to participants now, 86 under way, 19 of them phase 3. Psoriasis · United States.

Planned enrollment
12th of 673
1,680 · median 77
Started
2025
with 24 others
Phase 3
188 of 764
6 open now
Primary completion
2028-11
later than 66 of 85 live
Registered
728th of 764
by date

Among the 764 studies in Psoriasis with a site in United States, this one is the 12th largest by planned enrollment of the 673 interventional ones that give a count, is one of 25 that started in 2025, is one of 188 in phase 3, reaches primary completion later than 66 of the 85 other live ones, and was the 728th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

55 of the 764 studies in Psoriasis with a site in United States are open now. Recruiting first, the newest first:

50 more — sign in →

All 55 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 764 studies in Psoriasis with a site in United States, or all of them as a file.
02

Study summary

The objective of the ESK-001-018 long term extension is to evaluate the safety and efficacy of ESK-001 over time. The scientific questions it aims to answer are:

  • How safe is taking ESK-001 long-term in people with moderate to severe plaque psoriasis?
  • Does taking ESK-001 long-term reduce the severity of people's plaque psoriasis?

Patients will enter the long-term extension study following completion of one of the parent studies (ESK-001-016 or ESK-001-017) and will receive open-label ESK-001 twice daily for 24 weeks. After 24 weeks, the first 200 patients meeting at least PASI-75 clinical response will be randomly assigned to receive ESK-001 or placebo. At any point during this time, the patients losing the initial clinical response may return to the open-label ESK-001 treatment. Patients who complete Week 48 will return to open-label ESK-001 treatment and they will receive ESK-001 until the end of the study or discontinuation. All the remaining patients not meeting the entry criteria for the randomized withdrawal phase will continue to receive open-label ESK-001 for the remainder of the study.

Patients taking part in the study must be men or women aged at least 18 years old and have completed a previous (parent) study of ESK-001 in moderate to severe plaque psoriasis.

Patients must consent and agree to:

  • ensure drug daily compliance until end of study or discontinuation.
  • visit the clinic for checkups and assessments.
  • provide blood and urine samples.
03

Conditions studied

  • Plaque Psoriasis
  • Psoriasis (PsO)
  • Psoriasis
  • Moderate Psoriasis
  • Severe Psoriasis

Browse trials for

Keywords

  • Psoriasis
  • PASI
  • Safety
  • ESK-001
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males or females, age ≥18 years
  2. Completed either of the two previous (parent) studies of ESK-001 (ESK-001-016 or ESK-001-017)
  3. ESK-001 safety and tolerability were acceptable in the parent study
  4. Women of (WOCBP) and males who are sexually active with WOCBP must agree to adhere to highly effective methods of for the entirety of the study

Exclusion criteria

Exclusion Criteria:

  1. Pregnant, lactating, or planning to get pregnant during the study period
  2. Any acute or chronic illness/condition or evidence of an unstable clinical condition that in the Investigator's judgment will substantially increase the risk to the patient if they continue to receive ESK-001 treatment in this extension study
  3. Deemed by the Investigator to be inappropriate for the study or unable to comply with the protocol
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,680 participants (estimated)

Study arms

  • Experimental
    Open-Label ESK-001

    Open-Label ESK-001 administered as an oral tablet

    Drug: Open-Label Envudeucitinib

  • Experimental
    Blinded ESK-001

    Blinded ESK-001 administered as an oral tablet

    Drug: Blinded Envudeucitinib

  • Placebo comparator
    Placebo

    Matching placebo administered as an oral tablet

    Drug: Placebo

Interventions

  • DrugOpen-Label Envudeucitinib

    Open-Label ESK-001

  • DrugBlinded Envudeucitinib

    Blinded ESK-001 during Randomized Treatment Withdrawal Period

  • DrugPlacebo

    Placebo during Randomized Treatment Withdrawal Period

06

What researchers measure

Primary outcomes

  1. To assess the long-term safety and tolerability of ESK-001 throughout the duration of the study

    Incidence and severity of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)

    Time frame: Approximately 4 years

Secondary outcomes

  1. To assess the long-term efficacy of ESK-001 using the Psoriasis Area and Severity Index (PASI-75)

    Proportion of patients achieving ≥75% reduction in PASI

    Time frame: 24, 48, 72, and 96 weeks

  2. To assess the long-term efficacy of ESK-001 using the Psoriasis Area and Severity Index (PASI-90)

    Proportion of patients achieving ≥90% reduction in PASI

    Time frame: 24, 48, 72, and 96 weeks

  3. To assess the long-term efficacy of ESK-001 using the Psoriasis Area and Severity Index (PASI-100)

    Proportion of patients achieving 100% reduction in PASI

    Time frame: 24, 48, 72, and 96 weeks

  4. To assess the long-term efficacy of ESK-001 using the Static Physician's Global Assessment (sPGA 0/1)

    Proportion of patients achieving a score of 0 or 1 on sPGA

    Time frame: 24, 48, 72, and 96 weeks

  5. To assess the long-term efficacy of ESK-001 based on change in Psoriasis Area and Severity Index (PASI)

    Change in Psoriasis Area and Severity Index (PASI) from baseline assessments

    Time frame: 24, 48, 72, and 96 weeks

  6. To assess the long-term efficacy of ESK-001 based on change in Affected Body Surface Area (%BSA)

    Change in affected body surface area (%BSA) from baseline assessments

    Time frame: 24, 48, 72, and 96 weeks

  7. To characterize the loss of PASI-75 response following withdrawal of ESK-001 treatment (only for patients randomized to the treatment withdrawal phase)

    Median time to loss of PASI-75 response

    Time frame: Week 48

  8. To characterize the loss of PASI-90 response following withdrawal of ESK-001 treatment (only for patients randomized to the treatment withdrawal phase)

    Median time to loss of PASI-90 response

    Time frame: Week 48

  9. To characterize the loss of sPGA-0/1 response following withdrawal of ESK-001 treatment (only for patients randomized to the treatment withdrawal phase)

    Median time to loss of sPGA-0/1 response

    Time frame: Week 48

  10. To assess the change in quality of life (QoL) using Dermatology Life Quality Index after long-term ESK-001 administration

    Proportion of patients achieving a DLQI-0/1 score of 0 (no effect) or 1 (minimal effect)

    Time frame: Week 24, Week 48, and Week 72

07

Study locations

268 sites

Showing the first 100 of 268 sites across 16 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Undecided — The Sponsor Alumis Inc. is a clinical-stage biopharmaceutical company that has not yet adopted an Individual Participant Data (IPD) sharing plan.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Nov 2028, 46 months after the start.

Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's planned 46 months is above that.

Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 27, 2025
First posted
Feb 26, 2025
StartActual
Jan 8, 2025
Primary completionEst.
Nov 2028
CompletionEst.
Nov 2028
Last update
Apr 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06846541
Lead sponsor
Alumis Inc
Responsible party
Sponsor
First posted
Feb 26, 2025
Start date
Jan 8, 2025
Primary completion
Nov 2028 (estimated)
Completion
Nov 2028 (estimated)
Last update
Apr 13, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion